DGAP-News: Eckert & Ziegler: Steady Growth also for 1st Half of 2011

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Half Year Results
Eckert & Ziegler: Steady Growth also for 1st Half of 2011

02.08.2011 / 07:45

---------------------------------------------------------------------

Berlin, August 02, 2011. The second quarter 2011 developed again successful
for the Eckert & Ziegler Group (ISIN DE0005659700), a specialist for
isotope applications in medicine, science and industry. The revenue was
exceeded slightly compared with the second quarter of 2010 and the profit
after taxes and minorities rose by 13%. Together with the stronger first
quarter of 2011 the best half-year results in the history of the company
are produced. The revenue increased by 5% to EUR 55.8 million compared with
the first six months of the previous year. The EBIT rose by 19% to EUR 11.9
million and the results after taxes and minorities increased by 28% to EUR
6.6 million. Earnings per share for the first half-year in 2011 are EUR
1.26 per share.

The Isotope Products segment accounts for the greatest share of the total
results. The revenue rose by 9% here. All product categories recorded
growth. In the ratio to the revenue the costs only increased less than
proportionate owing to economies of scale. Thus, EBIT could be increased by
19%.

The Radiopharma segment recorded the strongest growth. Increases were also
achieved here in all product lines. In total the segment increased the
half-year revenue by 25% to EUR 12.4 million. Particularly pleasing in this
context is the group-wide maximum gross profits of 60% so that here, even
more than in the segment Isotope Products, a large part of the growth in
revenue is reflected in the profits.

The Radiation Therapy segment (previously: Therapy) could not as expected
achieve the record revenue of the previous year. In 2010, profits from a
one-time sale to Russia gave a boost to earnings. Comparable are therefore
only the figures within the year 2011. The revenue remained almost constant
compared with the previous quarter. It was nevertheless possible to
increase the profit as the sales and management costs fell. Detailed
statements relating to the Radiation Therapy segment can be taken from the
semi-annual report of Eckert & Ziegler BEBIG S.A. (previously: IBt S.A.)
which is published at the same time (www.bebig.eu). In the Profit and Loss
segment there are smaller shifts and valuation differences between the
Eckert & Ziegler Group and the BEBIG financial statements which are
presented in the table below.

The revenue with external customers is constant compared with the previous
year in the Environmental Services segment. As however orders are also
placed within the Group and moreover costs were saved there are no losses
suffered any more as opposed to the previous year.

For the fiscal year 2011 the revenue target is EUR 110 to 120 million. The
Board of Directors reinforces its profit forecast of EUR 2.00 per share
(results after taxes and minorities >EUR 10 million). By the end of 2014
the board of directors is expecting a profitable increase in sales to
around EUR 200 million per year.

With around 560 employees the Eckert & Ziegler Group belongs to the largest
providers of isotope components for radiation therapy and nuclear medicine
worldwide.

If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de 


End of Corporate News

---------------------------------------------------------------------

02.08.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                      
Company:     Eckert & Ziegler Strahlen- und Medizintechnik AG             
             Robert-Rössle-Str.10                                         
             13125 Berlin                                                 
             Germany                                                      
Phone:       49 30 941084-138                                             
Fax:         49 30 941084-112                                             
E-mail:      karolin.riehle@ezag.de                                       
Internet:    www.ezag.de                                                  
ISIN:        DE0005659700                                                 
WKN:         565970                                                       
Listed:      Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;  
             Freiverkehr in Berlin, Düsseldorf, Hamburg, München          
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
133957 02.08.2011